Current Good Tissue Practice (cGTP) — 21 CFR Part 1271 Subpart D

Current Good Tissue Practice (cGTP) — 21 CFR Part 1271 Subpart D

What is cGTP?
Current Good Tissue Practice (cGTP) refers to the regulatory requirements under 21 CFR Part 1271 Subpart D that govern the methods, facilities, and controls used for the processing, storage, labeling, packaging, and distribution of human cell and tissue products.

Current Good Tissue Practice (cGTP) requirements establish manufacturing safeguards applicable to Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps).

Licensed medical professionals and organizations seeking regulatory clarity or documentation transparency may request additional educational materials and supporting information through the contact page.

These requirements are codified in 21 CFR Part 1271 Subpart D and operate within the broader regulatory framework defined under 21 CFR Part 1271.

cGTP standards are intended to reduce the risk of communicable disease transmission by requiring appropriate controls across recovery, processing, storage, labeling, packaging, and distribution.

For a structured overview of regulatory criteria and safeguards, see the Regulatory Resource Library.

Inconsistent classification or incomplete documentation may influence how biologic products are evaluated under applicable regulatory standards.

Documentation and Regulatory Education

Licensed medical professionals may request structured documentation review and regulatory overview materials prior to engaging with biologic suppliers.

This process supports documentation clarity, classification alignment, and sourcing transparency under 21 CFR Part 1271.

Credential verification is required prior to documentation access.

Request Regulatory Information

Provider Credential Verification Portal

Schedule a Professional Consultation

Requests are reviewed to confirm professional credentials and determine appropriate documentation access pathways.

This information is for educational purposes only. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease. For use by licensed medical professionals.
Current Good Tissue Practice framework under 21 CFR Part 1271 Subpart D
Educational reference illustrating manufacturing safeguards under Current Good Tissue Practice (cGTP).

Purpose of cGTP Requirements

  • Recovery controls
  • Processing controls
  • Storage conditions
  • Labeling and packaging
  • Distribution safeguards

These controls are intended to prevent contamination or cross-contamination of HCT/Ps.

Manufacturing Controls (Subpart D)

  • Environmental monitoring
  • Equipment maintenance
  • Supply controls
  • Recordkeeping and traceability
  • Complaint handling

Quality System Elements

  • Standard operating procedures (SOPs)
  • Personnel training
  • Traceability systems
  • Deviation handling
  • Corrective action processes

Role in Section 361 Eligibility

Regulatory Oversight

  • FDA inspections
  • Documentation review
  • Traceability verification
  • Quality system evaluation

Observations related to cGTP may result in regulatory actions such as warning letters or required corrective measures.

Related Regulatory Topics

Regulatory Notice

This information is for educational purposes only.

Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease.

For use by licensed medical professionals.